DATE: January 31, 2024

TO: Hospitals, Local Health Departments, Laboratories, Emergency Rooms, Family Medicine, Pediatrics, Adolescent Medicine, Internal Medicine, Infectious Disease, Infection Control Practitioners, and Primary Care Providers

FROM: New York State Department of Health Division of Vaccine Excellence

HEALTH ADVISORY: BE VIGILANT FOR MEASLES CASES

The New York State Department of Health is forwarding a communication issued by the Centers for Disease Control and Prevention to share information about the following:

- Outbreaks have occurred globally, and there have been recently reported cases in New York City and neighboring states (Pennsylvania and New Jersey).
- Despite the United States having declared measles "eliminated" in 2000, outbreaks have continued to occur, including one involving hundreds of cases in New York State as recently as 2019.
- Providers should be on alert for patients who have: (1) febrile rash illness and symptoms consistent with measles (e.g., cough, coryza, or conjunctivitis), and (2) have recently traveled abroad, especially to countries with ongoing measles outbreaks.
- Measles is one of the most contagious infections and individuals are contagious from four days before to four days after rash onset.
- Report patients with suspected measles immediately to the local health department of the patient's residence. If in New York City, report persons with suspected measles immediately to the New York City Department of Health and Mental Hygiene at 866-692-3641. Do not wait for laboratory confirmation to report.
  - If you have urgent questions regarding measles during evenings, weekends, or holidays, call 866-881-2809.
- Educate patients about measles-containing vaccines. This is especially important before international travel.

Clinical Signs and Symptoms
Measles typically presents in adults and children as an acute viral illness characterized by fever and generalized maculopapular rash (Figure 1). Signs and symptoms appear 7 to 21 days after initial exposure. The prodrome may include cough, coryza, and conjunctivitis. The rash usually starts on the face, proceeds down the body, and may include the palms and soles. The rash initially appears discrete but may become confluent and lasts several days (Figure 2,3). Symptoms may be mild, absent, or atypical in persons who have some degree of immunity to measles virus before infection (e.g., in previously vaccinated persons). Serious side effects of measles can include pneumonia, encephalitis, hospitalization, and death.
Transmission and Infection Control
- To promptly identify suspected cases of measles and prevent exposures, consider screening patients for rash with fever at the point of entry of a healthcare facility and inquire about recent international or domestic travel and possible exposure to measles.
- Immediately institute standard and airborne precautions for patients with known or suspected measles and call ahead for patients being referred to other healthcare facilities to prevent healthcare-associated exposures.
- Place the patient in a single-patient airborne infection isolation room.
  - If a single-patient airborne infection isolation room is unavailable, place the patient in a private exam room with the door closed and have them wear a mask. After the patient leaves, it should remain vacant for at least two hours.

Reporting
Suspected measles cases must be reported immediately to the local health department of the patient’s residence. The local health department in New York State (outside of New York City) can assist in arranging testing at the Wadsworth Center Laboratory, and for specimens to arrive at the lab within 24-hours of collection, when feasible.

Specimen Collection
Follow Wadsworth Center Laboratory’s tip sheet and collect either a nasopharyngeal swab or throat swab for reverse transcription polymerase chain reaction (RT-PCR), as well as a blood specimen for serology, from patients with suspected measles for testing at the lab. Follow the packaging and shipping instructions on the tip sheet. However, if sending serology only, address to: Diagnostic Immunology Laboratory at David Axelrod Institute Wadsworth, 120 New Scotland Ave, Albany, NY 12208.

Public Health Action
Those who are infected should be isolated for four days after they develop a rash; standard and airborne precautions should be followed in healthcare settings. People who are suspected to be exposed to measles who cannot readily show that they have evidence of immunity against measles should be offered post-exposure prophylaxis (PEP).

To potentially provide protection or modify the clinical course of disease among susceptible persons, either administer MMR vaccine within 72 hours of initial measles exposure, or immunoglobulin (IG) within six days of exposure. Do not administer MMR vaccine and IG simultaneously, as this practice invalidates the vaccine.
Stay Alert for Measles Cases

Between December 1, 2023 and January 23, 2024, the Centers for Disease Control and Prevention (CDC) was notified of 23 confirmed U.S. cases of measles, including seven direct importations of measles by international travelers and two outbreaks with more than five cases each. Most of these cases were among children and adolescents who had not received a measles-containing vaccine (MMR or MMRV), even if age eligible.

Due to the recent cases, healthcare providers should be on alert for patients who have: (1) febrile rash illness and symptoms consistent with measles (e.g., cough, coryza, or conjunctivitis), and (2) have recently traveled abroad, especially to countries with ongoing measles outbreaks. Infected people are contagious from 4 days before the rash starts through 4 days afterwards.

Measles cases often originate from unvaccinated or undervaccinated U.S. residents who travel internationally and then transmit the disease to people who are not vaccinated against measles. The increased number of measles importations seen in recent weeks is reflective of a rise in global measles cases and a growing global threat from the disease.

Recommendations for Healthcare Providers

1. **Isolate:** Do not allow patients with suspected measles to remain in the waiting room or other common areas of the healthcare facility; isolate patients with suspected measles immediately, ideally in a single-patient airborne infection isolation room (AIIR) if available, or in a private room with a closed door until an AIIR is available. Healthcare providers should be adequately protected against measles and should adhere to standard and airborne precautions when evaluating suspect cases regardless of their vaccination status.

2. **Notify:** Immediately notify local or state health departments about any suspected case of measles to ensure rapid testing and investigation. Measles cases are reported by states to CDC through the National Notifiable Diseases Surveillance System (NNDSS) and can also be reported directly to CDC at measlesreport@cdc.gov.

3. **Test:** Follow CDC’s testing recommendations and collect either a nasopharyngeal swab or throat swab for reverse transcription polymerase chain reaction (RT-PCR), as well as a blood specimen for serology from all patients with clinical features compatible with measles. RT-PCR is available at CDC, at many state public health
laboratories, and through the APHL/CDC Vaccine Preventable Disease Reference Centers.

4. **Manage:** In coordination with local or state health departments, provide appropriate measles post-exposure prophylaxis (PEP) to close contacts without evidence of immunity, either MMR or immunoglobulin. The choice of PEP is based on elapsed time from exposure or medical contraindications to vaccination.

5. **Vaccinate:** Make sure all your patients are up-to-date on measles vaccine, especially before international travel. People 6 months of age or older who will be traveling internationally should be protected against measles.

**For More Information:**
- For Healthcare Professionals – Diagnosing and Treating Measles | CDC
- Interim Infection Prevention and Control Recommendations for Measles in Healthcare Settings | CDC
- Measles – Vaccine Preventable Diseases Surveillance Manual | CDC
- Plan for Travel – Measles | CDC
- Measles Lab Tools | CDC
- Measles Serology | CDC
- Measles Specimen Collection, Storage, and Shipment | CDC
- CDC Measles Toolkit for Health Departments

The Office of Emergency Risk Communication in the Office of Communications is responsible for the management of all COCA Products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov

**Clinician Outreach and Communication Activity**—resources for healthcare providers
**COCA RSS Feed**—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
**Crisis & Emergency Risk Communication Training**—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
**Health Alert Network**—CDC’s primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories

CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.